Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal application of salvianolic acid A

A technology of salvianolic acid and medicine, applied in the field of medical application of salvianolic acid A, can solve problems such as increased cAMP content

Inactive Publication Date: 2017-05-10
威海恒基伟业信息科技发展有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, salvianolic acid A can promote the increase of cAMP content in platelets and / or plasma, inhibit calcium ion concentration, inhibit adenylate activating enzyme, and inhibit platelet cytoplasmic calcium ion ([Ca 2+ ]i) The inhibitory effect of the concentration has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0013]Experimental example 1: Effect of salvianolic acid A on platelet aggregation with different inducers in vitro

[0014] 1. Materials

[0015] Salvianolic acid A, provided by Shandong Target Drug Research Co., Ltd.

[0016] Acetylsalicylic acid (ASA), sigma company A5376

[0017] 3-isobutyl-1-methylxanthine (IBMX), sigma company I5879

[0018] Adenosine diphosphate (ADP), sigma company A2754

[0019] Thrombin (Thr), sigma company T4648

[0020] Arachidonic acid (AA), sigma company BMA001

[0021] Ethylenediaminediacetic acid disodium salt (EDTA.Na 2 ), Tianjin No.1 Chemical Reagent Factory, batch number: 080616

[0022] Ethylene glycol diethyl ether diamine tetraacetic acid (EGTA), sigma E4378

[0023] Hepes, sigma H3375

[0024] Bovine Serum Albumin V Fraction (BSA), Roche 738328

[0025] Sodium citrate hydrochloride, Sinopharm Chemical Reagent Co., Ltd., batch number: F20071212

[0026] Anhydrous Calcium Chloride (CaCl 2 ), Sinopharm Chemical Reagent Co., Ltd....

experiment example 2

[0041] Experimental example 2: Effects of salvianolic acid A on the cAMP content in platelets and the activities of phosphodiesterase and adenylate cyclase in platelets

[0042] 1. Effect of salvianolic acid A on cAMP content in platelets

[0043] 1.1 Materials

[0044] Salvianolic acid A, provided by Shandong Target Drug Research Co., Ltd.

[0045] 3-isobutyl-1-methylxanthine (IBMX), sigma company, batch number: I5879, was dissolved in a water bath at 100° C. with physiological saline, and the concentration was 10 mM.

[0046] Adenosine diphosphate (ADP), Sigma Company, batch number: A2754, was prepared into a solution with a concentration of 300 μmol / l with physiological saline.

[0047] Disodium ethylenediaminetetraacetic acid (EDTA), Tianjin No. 1 Chemical Reagent Factory, batch number: 080616, prepared with deionized water.

[0048] Ethylene glycol diethyl ether diamine tetraacetic acid (EGTA), sigma company, lot number: E4378

[0049] Hepes, sigma company, lot number...

experiment example 3

[0088] Experimental example 3: Determination of salvianolic acid A on free [Ca2+]i in platelets

[0089] 1. Materials

[0090] Salvianolic acid A, provided by Shandong Target Drug Research Co., Ltd.

[0091] Adenosine diphosphate (ADP): sigma A2754

[0092] Acetyl hydroxymethyl ester (Fura-2 / AM): product of sigma

[0093] TritonX-100, purchased from Huamei Bioengineering Company

[0094] Animals: SPF-grade SD rats, male, weighing 300-350 g, were purchased from the Experimental Animal Center of Peking University Health Science Center, certificate number: SCXK (Beijing) 2006-0008.

[0095] 2. Methods and Results

[0096] Blood was collected from the abdominal aorta of rats and anticoagulated with 3.8% sodium citrate (1:9) to prepare PRP. Take PRP, add Fura-2 / AM at a final concentration of 2 μmol / L, and shake at 37°C for 30 minutes in the dark. with no Ca 2+ Wash twice with Tyrode-Hepes solution to wash off the excess Fura-2 / AM outside the platelets, and finally suspend i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, discloses novel application of salvianolic acid A, and particularly the application of salvianolic acid A in preparing a medicine for increasing content of CAMP (Cyclic Adenosine Monophosphat) in thrombocyte and / or blood plasma, a medicine for inhibiting activity of phosphodiesterase in thrombocyte, a medicine for promoting activity of adenylate activating enzymes, and a medicine for inhibiting concentration of platelet cytoplasmic calcium, particularly a medicine for preventing or treating thrombolysis and myocardial Ischemia reperfusion injury caused by percutaneous coronary intervention operation or coronary artery bypass grafting and the like.

Description

technical field [0001] The present invention relates to a new medical application of salvianolic acid A, specifically referring to its application in the preparation of medicines for treating cardiovascular and cerebrovascular diseases. Background technique [0002] cAMP widely exists in various cells and plays an important role in regulating the function and metabolism of cells. Pharmacological tests have shown that exogenous cAMP has the functions of relaxing smooth muscle, dilating blood vessels, improving liver function, promoting nerve regeneration, inhibiting the division of outer skin cells and transforming abnormal cells, promoting the activity of respiratory chain oxidase, improving myocardial hypoxia, etc. . Elevating cAMP levels can be used to treat the following conditions, including but not limited to: thromboembolic disease, peripheral vascular disease, artificial heart valve, congestive heart failure, coronary artery bypass surgery, viral myocarditis, arrhyth...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/216A61P7/02A61P9/00A61P9/04A61P9/06A61P37/04A61P25/24A61P1/16A61P29/00A61P11/06A61P9/10A61P9/12A61P3/10A61P5/16
CPCA61K31/216
Inventor 蔡颖
Owner 威海恒基伟业信息科技发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com